Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Tiziana Life Sciences Ltd (TLSA) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.85, with a market capitalisation of $113.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.81 to $2.35. This page covers its latest market performance, valuation, price trends and company information.
$113.29M | |
$0.87 | |
$16.79 | |
$0.41 | |
$0.85 | |
826.00 | |
582.66K | |
-- | |
$2.35 | |
$0.81 | |
-- | |
-- |
Tiziana Life Sciences Ltd (TLSA) is trading at $0.85 in pre-market trading as of 2026-09-16 12:03:00, down 0.82% ($0.01) from the previous close of $0.85
Pre-market trading shows how investors are pricing TLSA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Tiziana Life Sciences Ltd (TLSA) moved from $1.02 to $0.85, representing a decline of 17.16% ($0.18).
The stock traded between $0.81 and $1.06 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 489.25 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.3%
TLSA is currently trading at $0.85, placing it 2.3% of the way from its 52-week low of $0.81 to its 52-week high of $2.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tiziana Life Sciences Ltd (TLSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.